Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice

Authors:

Abstract
This manuscript describes an extended work on the Newcastle disease virus (NDV)-based vaccine focusing on multivalent formulations of NDV vectors expressing different prefusion-stabilized versions of the spike proteins of different SARS-CoV-2 variants of concern (VOC). We demonstrate here that this low-cost NDV platform can be easily adapted to construct vaccines against SARS-CoV-2 variants.
All Related Versions
Funding Information
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400008C)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (75N93021C00014)
  • HHS | National Institutes of Health (DK130425/DK/NIDDK)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID R21AI157606)
  • Anonymous philanthropist to Mount Sinai (-)